Literature DB >> 458375

The requirement for adherent cells in the Fc fragment-induced proliferative response of murine spleen cells.

E L Morgan, W O Weigle.   

Abstract

The proliferative response of mouse B lymphocytes induced by Fc fragments was found to be dependent upon an adherent cell population. The adherent cell is esterase positive, irradiation resistant, and not susceptible to lysis by anti-thymus serum and complement. The mechanism(s) by which Fc fragments induce B-cell proliferation could be the result of the interaction of Fc with both B cells and adherent cells or with adherent cells which then release factors that trigger the B cells to proliferate. Spleen cells from the C3H/HeJ mouse were shown to be unable to respond to Fc fragments. The addition of adherent cells from either C3H/St or C3H/HeN mice to adherent cell depleted C3H/HeJ cells enabled them to respond to Fc, indicating the defect was in the adherent cell population.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 458375      PMCID: PMC2185629          DOI: 10.1084/jem.150.2.256

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  32 in total

1.  Genetic control of responses to bacterial lipopolysaccharides in mice. II. A gene that influences a membrane component involved in the activation of bone marrow-derived lymphocytes by lipipolysaccharides.

Authors:  J Watson; R Riblet
Journal:  J Immunol       Date:  1975-05       Impact factor: 5.422

2.  A procedure for removing red cells and dead cells from lymphoid cell suspensions.

Authors:  W F Davidson; C R Parish
Journal:  J Immunol Methods       Date:  1975-06       Impact factor: 2.303

3.  Difference in B cell mitogen responsiveness between closely related strains of mice.

Authors:  D L Rosenstreich; L M Glode
Journal:  J Immunol       Date:  1975-09       Impact factor: 5.422

4.  The role of macrophages in the generation of T helper cells. V. Evidence for differential activation of short-lived T1 and long-lived T2 lymphocytes by the macrophage factors GRF and NMF.

Authors:  P Erb; P Vogt; B Meier; M Feldmann
Journal:  J Immunol       Date:  1977-07       Impact factor: 5.422

5.  The role of the macrophage as the stimulator cell in contact sensitivity.

Authors:  D W Thomas; G Forni; E M Shevach; I Green
Journal:  J Immunol       Date:  1977-05       Impact factor: 5.422

6.  Cellular and genetic control of antibody responses in vitro. IV. Expression of Ia antigens on accessory cells required for responses to soluble antigens including a response under Ir gene control.

Authors:  R J Hodes; G B Ahmann; K S Hathcock; H B Dickler; A Singer
Journal:  J Immunol       Date:  1978-10       Impact factor: 5.422

7.  Macrophages are required for the dextran-sulfate induced activation of B lymphocytes.

Authors:  U C Persson; L L Hammarström; C I Smith
Journal:  J Immunol       Date:  1977-09       Impact factor: 5.422

8.  The in vitro immune response to a T-independent antigen. I. The effect of macrophages and 2-mercaptoethanol.

Authors:  A A Nordin
Journal:  Eur J Immunol       Date:  1978-11       Impact factor: 5.532

9.  B-lymphocytes activation by the Fc region of IgG.

Authors:  M A Berman; W O Weigle
Journal:  J Exp Med       Date:  1977-07-01       Impact factor: 14.307

10.  The role of surface IgD in the response to thymic-independent antigens.

Authors:  I M Zitron; D E Mosier; W E Paul
Journal:  J Exp Med       Date:  1977-12-01       Impact factor: 14.307

View more
  16 in total

1.  Treatment with low doses of polyclonal immunoglobulin improves B cell function during immune reconstitution in a murine model.

Authors:  Ana Barahona Afonso; Lígia Neves Justo; Ana Cristina Queirós; Constantin Fesel; Maria Salomé Cabral; Maria Gomes da Silva; Luis Porrata; Svetomir Markovic; Ana Elisabete Pires; Cristina João
Journal:  J Clin Immunol       Date:  2012-09-30       Impact factor: 8.317

2.  Isolation and identification of a biologically active peptide derived from the CH3 domain of human IgG1.

Authors:  E L Morgan; T E Hugli; W O Weigle
Journal:  Proc Natl Acad Sci U S A       Date:  1982-09       Impact factor: 11.205

3.  Potentiation of specific human in vitro immune responses by the Fc portion of human immunoglobulin.

Authors:  E L Morgan; W O Weigle
Journal:  Clin Exp Immunol       Date:  1983-08       Impact factor: 4.330

Review 4.  Fc receptor--more answers, more questions.

Authors:  L Fornůsek; V Vĕtvicka
Journal:  Folia Microbiol (Praha)       Date:  1984       Impact factor: 2.099

5.  Inhibitory mechanism of the proliferative response of B lymphocytes: suppression of the proliferation induced by anti-mu antibody and BSF1 by immune complexes.

Authors:  M Miyama-Inaba; T Ohno; K Inaba; K Ajisaka; R Suzuki; K Kumagai; T Masuda
Journal:  Immunology       Date:  1987-05       Impact factor: 7.397

6.  Enhancement of T lymphocyte functions by Fc fragments of immunoglobulins. I. Augmentation of allogeneic mixed lymphocyte culture reactions requires I-A- or I-B-subregion differences between effector and stimulator cell populations.

Authors:  E L Morgan; M L Thoman; W O Weigle
Journal:  J Exp Med       Date:  1981-05-01       Impact factor: 14.307

7.  Polyclonal activation of human B lymphocytes by Fc fragments. I. Characterization of the cellular requirements for Fc fragment-mediated polyclonal antibody secretion by human peripheral blood B lymphocytes.

Authors:  E L Morgan; W O Weigle
Journal:  J Exp Med       Date:  1981-09-01       Impact factor: 14.307

8.  Lymphocyte cooperation is required for amplification of macrophage procoagulant activity.

Authors:  G A Levy; T S Edgington
Journal:  J Exp Med       Date:  1980-05-01       Impact factor: 14.307

9.  Selective proteolysis of immunoglobulins by mouse macrophage elastase.

Authors:  M J Banda; E J Clark; Z Werb
Journal:  J Exp Med       Date:  1983-04-01       Impact factor: 14.307

10.  Regulation of the immune response. I. The potentiation of in vivo and in vitro immune responses by Fc fragments.

Authors:  E L Morgan; S M Walker; M L Thoman; W O Weigle
Journal:  J Exp Med       Date:  1980-07-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.